- Home
- KXIN vs ASBP Comparison
KXIN vs ASBP Comparison
Compare KXIN & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KXIN | ASBP |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | China | United States |
| Employees | 13 | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 6.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KXIN | ASBP |
|---|---|---|
| Price | $4.00 | $5.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 52.4K | ★ 206.7K |
| Earning Date | 11-26-2019 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.11 | $0.05 |
| 52 Week High | $22.00 | $7.05 |
Technical Indicators
Market Signals| Indicator | KXIN | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 32.83 | 55.48 |
| Support Level | $3.32 | $0.19 |
| Resistance Level | $5.86 | $6.98 |
| Average True Range (ATR) | 0.37 | 0.88 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 7.22 | 69.29 |
Price Performance
Historical ComparisonAbout KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto dealership company mainly engaged in the sale of domestic and imported automobiles in China. The company provides new and used car buyers in China with access to a wide selection of used vehicles across its network of dealerships, with a focus on premium brands such as Audi, BMW, Mercedes-Benz, Land Rover, and Porsche. The company generates revenue from automobile sales and related services.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.